Recent 8-K filings for LLY

• May 20, 2026, 4:30 PM ET debt materiality 0.80 neutral item 8.01item 9.01

  Lilly completes $9B multi-tranche debt offering tied to Centessa acquisition

  Completed $9.0B aggregate principal debt offering across eight tranches of floating and fixed-rate notes due 2026-2066.

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo

  Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.

• February 4, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B

  Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.

• October 30, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand

  Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.

• August 7, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance

  Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.

• May 1, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance

  Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.

• February 12, 2025, 6:59 PM ET debt materiality 0.75 neutral item 8.01item 9.01

  Eli Lilly issues $6.5B of notes across 6 tranches; net proceeds ~$6.46B

  Issues $1B 4.550% notes due 2028, $1.25B 4.750% notes due 2030, $1B 4.900% notes due 2032.

• February 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue

  Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).

• January 14, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B

  2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.

• October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B

  Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.

• September 9, 2024, 7:59 PM ET leadership materiality 0.75 positive item 5.02item 9.01 ◈ executive_change

  Lilly appoints Lucas Montarce as EVP and CFO, effective Sept 9, 2024

  Lucas Montarce, 47, promoted from president of Spain/Portugal/Greece hub to CFO, effective immediately.

• August 8, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B

  Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).

• July 10, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×2

  Eli Lilly CFO Anat Ashkenazi resigns; Gordon Brooks interim CFO from July 15

  Anat Ashkenazi resigned as EVP and CFO to pursue opportunity outside pharma; stays through July for transition.

• June 5, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02item 9.01 ◈ executive_change

  Eli Lilly CFO Anat Ashkenazi resigns; to leave in July 2024

  Anat Ashkenazi resigns as EVP and CFO to pursue a career opportunity outside the pharmaceutical industry.

• April 30, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B

  Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

11 positive 0 negative 12 neutral

source · LLY on sec.gov